Abstract

Acinetobacter baumannii (AB) is increasingly becoming a clinically relevant organism due to the rising number of associated nosocomial infections. The therapeutic options are extremely minimal because of its ability to develop resistance to all available antimicrobials, including colistin (CST). Data on the clinical and microbiological characteristics of colistin-resistant A. baumannii infections remain scarce to date. In this prospective study, clinical isolates of colistin resistance among Acinetobacter strain was evaluated from the database of Microbiology Laboratory of King Khalid University Hospital, Saudi Arabia. In a total of 142 patients with 136 Acinetobacter isolates, Acintobacter baumannii was the predominant serotype 73% of the isolates and Acinetobacter lwoffii constituted 27% of the isolate . There was 8.5% colistin resistant isolates with colistin E-test MIC >4. The clinical characteristics were determined for colistin resistant Acinetobacter baumannii. All patients were critically ill and 64% of them were hositalized in the Intensive Care Unit (ICU). All patients have been previously given antibiotics. Other associated clinical characteristics included; morbid obesity and sleeve gastrectomy (21 %), mechanical ventilation and central venous catheter (50%). High mortality rate was found(28%). There is an increase of colistin resistance among clinical isolates of Acinetobacter baumannii causing serious infections especially in critically ill patients.

Highlights

  • Acinetobacter baumannii (AB) is one of the important multidrug resistant Gram-Negative nosocomial pathogens

  • Colistin resistance in Acinetobacter baumannii isolated from critically ill patients: clinical characteristics, antimicrobial susceptibility and outcome

  • Antimicrobial susceptibility testing The identification of the isolates and colistin susceptibility testing were performed by Vitek 2, and the colistin-resistant minimum inhibitory concentrations (MICs) were confirmed by E test methods, according to CLSI recommendations.[15]

Read more

Summary

Introduction

Acinetobacter baumannii (AB) is one of the important multidrug resistant Gram-Negative nosocomial pathogens. Colistin was considered as one of the last therapeutic options for treatment of the multiresistant Acinetobacter baumannii infection.[5] It has been recommended for the treatment of ventilator associated pneumonia caused by drug resistant gram negative organism.[6]. The objectives of the present study were to evaluate the clinical characteristics, antimicrobial susceptibility testing and outcomes of patients infected with colistin-resistant Acinetobacter baumannii. Methods: In this prospective study, clinical isolates of colistin resistance among Acinetobacter strain was evaluated from the database of Microbiology Laboratory of King Khalid University Hospital, Saudi Arabia. Conclusion: There is an increase of colistin resistance among clinical isolates of Acinetobacter baumannii causing serious infections especially in critically ill patients. Colistin resistance in Acinetobacter baumannii isolated from critically ill patients: clinical characteristics, antimicrobial susceptibility and outcome.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call